Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model.

Banerjee A, Patil S, Pawar MY, Gullapalli S, Gupta PK, Gandhi MN, Bhateja DK, Bajpai M, Sangana RR, Gudi GS, Khairatkar-Joshi N, Gharat LA.

Bioorg Med Chem Lett. 2012 Oct 1;22(19):6286-91. doi: 10.1016/j.bmcl.2012.07.077. Epub 2012 Aug 8.

PMID:
22944118
2.

Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors.

Gewald R, Rueger C, Grunwald C, Egerland U, Hoefgen N.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6652-6. doi: 10.1016/j.bmcl.2011.09.065. Epub 2011 Sep 21.

PMID:
21983442
3.

Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation.

Banerjee A, Yadav PS, Bajpai M, Sangana RR, Gullapalli S, Gudi GS, Gharat LA.

Bioorg Med Chem Lett. 2012 May 1;22(9):3223-8. doi: 10.1016/j.bmcl.2012.03.025. Epub 2012 Mar 23.

PMID:
22487174
4.

Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation.

Guo J, Watson A, Kempson J, Carlsen M, Barbosa J, Stebbins K, Lee D, Dodd J, Nadler SG, McKinnon M, Barrish J, Pitts WJ.

Bioorg Med Chem Lett. 2009 Apr 1;19(7):1935-8. doi: 10.1016/j.bmcl.2009.02.060. Epub 2009 Feb 21.

PMID:
19272774
5.

Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.

Redondo M, Brea J, Perez DI, Soteras I, Val C, Perez C, Morales-García JA, Alonso-Gil S, Paul-Fernandez N, Martin-Alvarez R, Cadavid MI, Loza MI, Perez-Castillo A, Mengod G, Campillo NE, Martinez A, Gil C.

J Med Chem. 2012 Apr 12;55(7):3274-84. doi: 10.1021/jm201720d. Epub 2012 Mar 16.

PMID:
22385507
6.

Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.

Lorthiois E, Bernardelli P, Vergne F, Oliveira C, Mafroud AK, Proust E, Heuze L, Moreau F, Idrissi M, Tertre A, Bertin B, Coupe M, Wrigglesworth R, Descours A, Soulard P, Berna P.

Bioorg Med Chem Lett. 2004 Sep 20;14(18):4623-6.

PMID:
15324876
7.

Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors.

Barnes MJ, Cooper N, Davenport RJ, Dyke HJ, Galleway FP, Galvin FC, Gowers L, Haughan AF, Lowe C, Meissner JW, Montana JG, Morgan T, Picken CL, Watson RJ.

Bioorg Med Chem Lett. 2001 Apr 23;11(8):1081-3.

PMID:
11327595
8.

Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.

Redondo M, Zarruk JG, Ceballos P, Pérez DI, Pérez C, Perez-Castillo A, Moro MA, Brea J, Val C, Cadavid MI, Loza MI, Campillo NE, Martínez A, Gil C.

Eur J Med Chem. 2012 Jan;47(1):175-85. doi: 10.1016/j.ejmech.2011.10.040. Epub 2011 Nov 4.

PMID:
22100138
9.

2-(Isopropylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as selective phosphodiesterase 7 inhibitors with potent in vivo efficacy.

Endo Y, Kawai K, Asano T, Amano S, Asanuma Y, Sawada K, Onodera Y, Ueo N, Takahashi N, Sonoda Y, Kamei N, Irie T.

Bioorg Med Chem Lett. 2015 May 1;25(9):1910-4. doi: 10.1016/j.bmcl.2015.03.031. Epub 2015 Mar 20.

PMID:
25866242
10.

Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.

Vergne F, Bernardelli P, Lorthiois E, Pham N, Proust E, Oliveira C, Mafroud AK, Royer F, Wrigglesworth R, Schellhaas J, Barvian M, Moreau F, Idrissi M, Tertre A, Bertin B, Coupe M, Berna P, Soulard P.

Bioorg Med Chem Lett. 2004 Sep 20;14(18):4607-13.

PMID:
15324874
11.

Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.

Kempson J, Pitts WJ, Barbosa J, Guo J, Omotoso O, Watson A, Stebbins K, Starling GC, Dodd JH, Barrish JC, Felix R, Fischer K.

Bioorg Med Chem Lett. 2005 Apr 1;15(7):1829-33.

PMID:
15780616
12.

Discovery and SAR study of 2-(4-pyridylamino)thieno[3,2-d]pyrimidin-4(3H)-ones as soluble and highly potent PDE7 inhibitors.

Endo Y, Kawai K, Asano T, Amano S, Asanuma Y, Sawada K, Ogura K, Nagata N, Ueo N, Takahashi N, Sonoda Y, Kamei N.

Bioorg Med Chem Lett. 2015 Feb 1;25(3):649-53. doi: 10.1016/j.bmcl.2014.11.090. Epub 2014 Dec 6.

PMID:
25529739
13.

Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities.

Redondo M, Soteras I, Brea J, González-García A, Cadavid MI, Loza MI, Martinez A, Gil C, Campillo NE.

Eur J Med Chem. 2013;70:781-8. doi: 10.1016/j.ejmech.2013.10.035. Epub 2013 Oct 22.

PMID:
24239625
14.

Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.

Bernardelli P, Lorthiois E, Vergne F, Oliveira C, Mafroud AK, Proust E, Pham N, Ducrot P, Moreau F, Idrissi M, Tertre A, Bertin B, Coupe M, Chevalier E, Descours A, Berlioz-Seux F, Berna P, Li M.

Bioorg Med Chem Lett. 2004 Sep 20;14(18):4627-31.

PMID:
15324877
15.

Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.

García AM, Brea J, Morales-García JA, Perez DI, González A, Alonso-Gil S, Gracia-Rubio I, Ros-Simó C, Conde S, Cadavid MI, Loza MI, Perez-Castillo A, Valverde O, Martinez A, Gil C.

J Med Chem. 2014 Oct 23;57(20):8590-607. doi: 10.1021/jm501090m. Epub 2014 Oct 8.

PMID:
25264825
16.

Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors.

Martínez A, Castro A, Gil C, Miralpeix M, Segarra V, Doménech T, Beleta J, Palacios JM, Ryder H, Miró X, Bonet C, Casacuberta JM, Azorín F, Piña B, Puigdoménech P.

J Med Chem. 2000 Feb 24;43(4):683-9.

PMID:
10691694
17.

Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.

Redondo M, Palomo V, Brea J, Pérez DI, Martín-Álvarez R, Pérez C, Paúl-Fernández N, Conde S, Cadavid MI, Loza MI, Mengod G, Martínez A, Gil C, Campillo NE.

ACS Chem Neurosci. 2012 Oct 17;3(10):793-803. doi: 10.1021/cn300105c. Epub 2012 Aug 8.

18.

SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors.

Revesz L, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Wolf R, Zimmerlin AG.

Bioorg Med Chem Lett. 2002 Aug 19;12(16):2109-12.

PMID:
12127515
19.

Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.

Peng H, Kumaravel G, Yao G, Sha L, Wang J, Van Vlijmen H, Bohnert T, Huang C, Vu CB, Ensinger CL, Chang H, Engber TM, Whalley ET, Petter RC.

J Med Chem. 2004 Dec 2;47(25):6218-29.

PMID:
15566292
20.

Identification of purine inhibitors of phosphodiesterase 7 (PDE7).

Pitts WJ, Vaccaro W, Huynh T, Leftheris K, Roberge JY, Barbosa J, Guo J, Brown B, Watson A, Donaldson K, Starling GC, Kiener PA, Poss MA, Dodd JH, Barrish JC.

Bioorg Med Chem Lett. 2004 Jun 7;14(11):2955-8.

PMID:
15125967
Items per page

Supplemental Content

Write to the Help Desk